The next stage of human machine collaboration AI
which learns and explains why
KEM® is the result of over 15 years of development for the life sciences at Ariana by experts in Machine Learning, Statistics, Biology, biomarker research and drug development.
“Ariana®: The Explainable Artificial Intelligence Driven Precision Medicine Company “
With KEM®, the signatures are easily interpretable
The KEM® approach identifies all possible signatures. The ranking and filtering are performed explicitly based on classification performance, signature simplicity (length), as well as any additional criteria such as biological knowledge (pathways enrichment) or clinical relevance (targeting specific patient subgroups) etc.
“Al Driven Knowledge Integration and Discovery Platform Aiming at Regulatory Strategy”
KEM® can identify all relevant relationships between variables
KEM® delivers unsupervised, unbiased, total data exploration.
This avoids many of the over-fitting issues, since there is no arbitrary optimization.
This can be compared with Random Forest, for example, where you may get rules that indicate that BMI should be < 17.003, which is unlikely to hold any medical meaning.
KEM® generates compact, interpretable signatures
with high specificity and sensitivity
They contribute to the increase of the specificity of the signature. Multiple ANDs are then combined through OR clauses, increasing sensitivity. In the FCA paradigm, there is no need for global convergence; hence the system can identify multiple local minima that are connected via ORs, enabling the effective and efficient analysis of heterogeneous data. The signatures identified by KEM® are comprised of a non-linear combination of AND and OR functions. The result is usually a much more compact signature
Latest Scientific Publications
” ANAVEX®2-73 (Blarcamesine) Currently in Phase 2b/3 Early)...
“Novel analytics framework for...